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Although the main role of 1,25-dihydroxyvitamin D3
[1,25-(OH)2D3] is to regulate calcium homeostasis, the
valuable therapeutic applications of this compound
have led to the search of new 1,25-(OH)2D3-vitamin D
receptor (VDR) ligands with less side effects. In this
work we have characterized seven 1,25-(OH)2D3 deriv-
atives (ZK136607, ZK161422, ZK157202, ZK159222,
ZK168492, ZK191732, and ZK168289). ZK157202 is an
agonist that gives a pattern similar to that of 1,25-
(OH)2D3 or ZK161422 in limited trypsin digestion as-
says, isable to recruitp160andVDR-interactingprotein
205 coactivators, is as potent as 1,25-(OH)2D3 to stim-
ulate vitamin D response element-dependent tran-
scription in HeLa cells, and acts as a superagonist in
human embryonic kidney 293T cells. This compound is
also more potent than the natural ligand to transre-
press the activation of the retinoic acid receptor 2
promoter by retinoic acid and the response of the col-
lagenase promoter to 4-12-O-tetradecanoylphorbol
13-acetate. ZK136607, ZK168492, ZK191732, and
ZK168289 have a profile similar to that of the partial
antagonist ZK159222. They induce an antagonistic-
type proteolytic pattern, do not recruit classical coac-
tivators, and have little transactivation potency. How-
ever, they act in a cell context-dependent manner
because they lack activity in HeLa cells while present-
ing some agonistic activity in human embryonic kidney
293T cells, or vice versa. Furthermore, some of these
compounds have a dissociated activity: they cannot
transactivate but they are as potent as 1,25-(OH)2D3 in
transrepression assays. Together our results demon-
strate the existence of novel VDR ligands with variable
biological functions and dissociated activity. They
should represent useful tools for studyingVDR function
andcouldhave therapeutic utility. (MolecularEndocrin-
ology 20: 3093–3104, 2006)
MOST OF THE biological actions of 1, 25-dihy-droxyvitamin D3 [calcitriol, 1,25-(OH)2D3] are
mediated by the receptor VDR (vitamin D receptor), a
member of the nuclear receptor superfamily of ligand-
dependent transcription factors (1). VDR acts prefer-
entially as a heterodimer with RXR (retinoid X receptor)
through binding to specific DNA sequences located at
regulatory regions of target genes, referred to as vita-
min D response elements (VDREs), normally com-
posed of two copies of the consensus AGGTCA motif
arranged as a direct repeat spaced by three nucleo-
tides (DR3). The nuclear receptors exhibit a modular
structure with several functional domains. The ligand
binding domain (LBD) contains the COOH-terminal
activation function (AF)-2 motif responsible for li-
gand-dependent transcriptional activation. In this
process, a critical step in nuclear receptor signaling
is the specific ligand-triggered induction of a con-
formational change within the LBD (2). This confor-
mational change results in ordered recruitment of
coactivators. The p160 coactivators [steroid recep-
tor coactivator (SRC)-1/nuclear coactivator 1, tran-
scriptional intermediary factor (TIF)2 or p300/cAMP
response element binding protein-binding protein/
activator for thyroid hormone and retinoid receptors
(ACTR)] have intrinsic histone acetyltransferase ac-
tivity and recruit additional histone acetyltransferase
and histone methyltranferase enzymes that alter
chromatin structure and modulate gene transcrip-
tion (3, 4). The receptors also recruit ATP-dependent
chromatin remodeling complexes, in the case of
VDR through direct interaction with WSTF, a com-
ponent of the WINAC complex (5). In addition, the
subunit VDR-interacting protein (DRIP)205/thyroid
hormone receptor-associated protein 220 (6) of the
DRIP/ thyroid hormone receptor-associated protein/
Mediator multiprotein complex is also recruited to
the core AF-2 receptor region in response to ligand
binding. It has been suggested that this complex
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could recruit the holoenzyme of the RNA polymer-
ase II to the target promoter (7).
In contrast to positively regulated genes, the mech-
anism by which nuclear receptors control the tran-
scription of negatively regulated genes is less well
understood. Proposed mechanisms include: compe-
tition of nuclear receptors with other transcription fac-
tor binding sites (8–10); receptor binding to the so
called negative regulatory elements in which the re-
ceptor interacts with other factors and recruits core-
pressors in a ligand-dependent manner (11); direct
interactions of nuclear receptors with transcription
factors such as the jun component of the AP-1 com-
plex, precluding a productive interaction with coacti-
vators or basal factors; and competition for limiting
amounts of transcriptional cofactors (1).
It is widely accepted that the fundamental role of
1,25-(OH)2D3 is to regulate calcium homeostasis (12).
However, many other biological functions of this vita-
min have been reported. Indeed, 1,25-(OH)2D3 plays
an important role in promoting cellular differentiation,
and in inhibiting the growth of several primary and
cultured cancer cell types, including T cell leukemias,
breast, prostate, and colon. It has also been proposed
that 1,25-(OH)2D3 and its synthetic analogs could be
useful in renal failure, vitamin D-dependent rickets
type I, osteoporosis, psoriasis, and certain autoim-
mune disorders such as multiple sclerosis or type 1
diabetes mellitus, although clinical data proving their
efficacy are not yet available (13, 14).
Although these findings suggest new therapeutic
possibilities for 1,25-(OH)2D3, deleterious side effects
such as hypercalcemia and soft tissue calcification
prevent the use of 1,25-(OH)2D3 as a therapeutic
agent. Therefore, a great deal of effort is being made
to develop new 1,25-(OH)2D3 analogs to dissociate
immunosuppressive/growth inhibitory/differentiation
properties and calcemic effects (15–18). Very recently,
novel noncalcemic, tissue selective, nonsecosteroidal
vitamin D receptor modulators (VDRMs) with improved
therapeutic indices have been obtained and charac-
terized (19).
In this study, we have compared the biological ac-
tions of seven 1,25-(OH)2D3 derivatives synthesized
by Schering AG (ZK136607, ZK161422, ZK157202,
ZK159222, ZK168492, ZK191732, ZK168289). We
have analyzed them for their agonistic and antagonis-
tic profile in vitro by monitoring the consequences of
ligand binding on receptor conformation and on the
recruitment of coactivator complexes. We have also
studied the effects of these compounds on transacti-
vation and transrepression of target gene promoters in
HeLa and human embryonic kidney (HEK) 293T cellu-
lar systems. In our study, ZK161422, described as an
agonist (20) and ZK159222, described as an antago-
nist with residual agonistic activity (21), were chosen
to compare with the effects promoted by the other
compounds and by the natural ligand. Our results
show that ZK157202 as well as ZK161422 have a clear
agonist profile and that they are even more potent than
1,25-(OH)2D3 in both transactivation and transrepres-
sion. However, other compounds have a profile similar
to that of the ZK159222 partial antagonist. They in-
duce an antagonistic-type proteolytic pattern, they are
unable to stimulate the recruitment of classical coac-
tivators, and they have little transactivation potency.
However, the agonistic effect appears to depend on
the cell context, and some of these compounds have
a dissociative activity: they cannot transactivate but
they are as potent as 1,25-(OH)2D3 in transrepression
assays. These dissociated 1,25-(OH)2D3 analogs, here
identified, are potential pharmacological tools in the
treatment and prevention of diseases in which VDRs
play a role.
RESULTS
Effect of 1,25-(OH)2D3 Analogs on Receptor
Conformation
The chemical structure, binding affinities and calcemic
activity of the 1,25-(OH)2D3 analogs used are shown in
Fig. 1. In an in vitro binding assay, unlabeled
ZK161422, ZK157202, ZK159222, and ZK191732
bound to VDR with a potency similar to that of 1,25-
(OH)2D3, whereas the other three ligands, ZK136607,
ZK168492, and ZK168289, bound the receptor with 1
order of magnitude lower than 1,25-(OH)2D3. On the
other hand, the calcemic activity of ZK161422 was
similar to that of the natural ligand, and that of
ZK157202 was ever higher, whereas the remaining
VDR ligands presented a markedly reduced calcemic
activity, measured both as urine calcium levels (Fig. 1)
and serum calcium levels (data not shown).
The ability of a ligand to induce transactivation of the
nuclear receptor can be described as a combination of
affinity, kinetics, and effectiveness at producing an
optimal protein conformation that facilitates the inter-
action with coactivator proteins, which consequently
results in stimulation of transcriptional activity through
various additional protein-protein interactions. We
performed limited protease digestion assays, in which
the interaction of a nuclear receptor with its ligand
protects the LBD against protease digestion, as a
method for characterizing functional VDR conforma-
tions. In this assay, VDR was subjected to limited
proteolysis with trypsin in the presence of a saturating
concentration of 1,25-(OH)2D3 or 1,25-(OH)2D3 ana-
logs (10 M). 1,25-(OH)2D3 generates a predominant
28-kDa fragment and a minor 23-kDa fragment repre-
sented in Fig. 2A as c1LPD or c3LPD, respectively
(conformations 1 and 3 of the limited protease diges-
tion). The agonist ZK161422, as well as the ZK157202
compound, induces the same proteolytic pattern as
1,25-(OH)2D3. However, the antagonist ZK159222, as
well as ZK136607, ZK168492, ZK191732, and
ZK168289, generates an additional fragment at 25 kDa
(designated c2LPD in Fig. 2A). c1LPD, c2LPD, and
c3LPD contain major parts of the LBD and its carboxyl-
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terminal truncations including from the trypsin-cutting
site after arginine 173 to either the carboxy terminus at
position 427 (c1LPD), to arginine 402 (c2LPD), or to
arginine 391 (c3LPD) (21). The 28- and 23-kDa fragments
reported here are thought to be the same previously
referred to as the 34- and 30-kDa fragments (22). The
28-kDa (21) or 34-kDa (22) fragments contain a 19-
residue portion of the hinge region and the entire LBD.
The other shorter fragments have the same N terminus
(after the arginine 173 trypsin-cutting site), but result from
further trypsinization near the C terminus. An increase in
the intensity of these fragments could be explained as a
failure of the ligand to coordinate the active closed con-
formation of the helices 10–12 of the LBD, leaving them
more susceptible to proteolytic cleavage. It has been
suggested that these shorter fragments are indicative of
a transcriptionally inactive state (22). In agreement with
others (23), our results suggest that ZK157202 could be
a potential agonist because the conformational change
in VDR induced by this analog is very similar to that
induced by 1,25-(OH)2D3 and the ZK161422 agonist (in
which the 28- or 30-kDa fragments are predominant). In
contrast, the proteolytic pattern of VDR observed in the
presence of ZK136607, ZK168492, ZK191732, and
ZK168289 is similar to that resulting from binding of the
antagonist ZK159222 to the VDR. ZK191732 has already
been demonstrated to behave as an antagonist of 1,25-
(OH)2D3-induced differentiation of Caco-2 cells (24).
Analysis of VDR-Coactivator Interactions in the
Presence of 1,25-(OH)2D3 and 1,25-(OH)2D3
Analogs
As an additional approach, we have analyzed the ag-
onistic or antagonistic potential of the 1,25-(OH)2D3
analogs based on their ability to induce an interaction
with coactivator proteins. For this purpose, we have
performed glutathione-S-transferase (GST) pull-down
and supershift assays. GST pull-down assays were
performed with bacterially produced GST-TIF2 (624–
1287), GST-ACTR (621–821), GST-SRC1 (570–780),
and GST DRIP205 (1770–2556) (fusion proteins con-
taining the coactivators nuclear receptor interaction
domain) and in vitro translated 35S-labeled VDR in the
presence of 100 nM 1,25-(OH)2D3 and 1,25-(OH)2D3
analogs (Fig. 2B). Supershift assays were performed
with the same coactivator proteins used in the pull-
down assays, in vitro translated VDR-RXR het-
erodimers, and a consensus DR3-type VDRE in the
presence of a saturating concentration of 1,25-
(OH)2D3 and 1,25-(OH)2D3 analogs (1 M) (Fig. 2C).
In both assays, 1,25-(OH)2D3, the agonist
ZK161422, and the ZK157202 compound were able to
Fig. 1. Structure and Characteristics of 1,25-(OH)2D3 Analogs
A, Chemical structures of 1,25-(OH)2D3 and the ZK compounds. Only the side chains that are different from that of the natural
ligand are depicted for some of the analogs. B, VDR ligand binding and calcemic activities. VDR ligand binding is expressed as
IC50 [concentration of ligand required to inhibit the binding of labeled 1,25-(OH)2D3 by 50%]. For the calcemic activities, the value
1, obtained with 0.03 g/kg/d of 1,25-(OH)2D3, is used as a reference. The doses that were equipotent with this concentration
of 1,25-(OH)2D3 are given for the ZK compounds. The maximal concentration used was 10 g/kg/d. 1,25-(OH)2D3 is shown as
1,25D.
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induce the interaction of VDR with the coactivators. In
contrast, ZK159222, ZK168492, ZK191732, and
ZK168289 were not able to promote significant coac-
tivator recruitment, either in solution or in a complex
with RXR on DNA. These results correlate with the
conformational change observed in the limited pro-
tease digestion assays described above.
Interestingly, ZK136607 was not able to induce in-
teraction of VDR with the coactivators in solution but
showed a slight capacity to promote VDR-coactivator
interaction in a complex with RXR on DNA. Although
this analog stabilized the VDR conformation c2LPD, it
is possible that in the presence of RXR and DNA,
ZK136607 is able to generate a more agonistic con-
formation in VDR, which allows a partial recruitment of
coactivators by this receptor. This ligand also shows a
reduced affinity by VDR as compared with 1,25-
(OH)2D3 in binding assays (see Fig. 1), but the con-
centration used in the supershift assays is high enough
to saturate the receptor; therefore, its reduced capac-
ity of coactivator recruitment cannot be secondary to
its decreased binding affinity.
Effect of VDR Ligands on Transactivation Assays
We performed transient transfections with a VDRE-
containing heterologous promoter (4VDRE TK-Luc)
in human HEK 293T (Fig. 3A) and HeLa cells (Fig. 3B),
transfected with receptors in the presence of graded
concentrations of 1,25-(OH)2D3 or ZK compounds.
1,25-(OH)2D3 induced reporter activity in a typical
dose-dependent manner, achieving the maximal ef-
fect (20-fold induction) at 10 nM in HEK 293T cells or at
100 nM in HeLa cells. As expected, the agonist
ZK161422 was as potent as 1,25-(OH)2D3 to transac-
tivate the DR3-containing plasmid. In addition, at low
doses, ZK157202 was even more potent than 1,25-
(OH)2D3. This superagonistic effect was more marked
in HEK 293T cells, achieving the maximal action at 1
nM. In contrast, the other compounds showed a null or
partial agonist activity. As expected, ZK159222 con-
sidered as a partial antagonist, only weakly activated
the promoter at the highest dose used. ZK136607
showed null (HEK 293T cells) or low activity (Hela
cells), and ZK168492 also showed more activity in
HeLa than in HEK 293 cells. In contrast, in HEK 293T,
but not in HeLa cells, ZK191732 and ZK168289 acti-
vated the promoter although always with less potency
than 1,25-(OH)2D3. Although a weaker increase of re-
porter activity was found in HeLa cells that were not
transfected with receptors, the transactivation profile
obtained with the different compounds was similar to
that shown in Fig. 3B (data not shown), demonstrating
Fig. 2. Effect of 1,25-(OH)2D3 Analogs on VDR Conformation and Coactivator Recruitment
A, Limited protease digestion assay. In vitro translated [35S]VDR preincubated with EtOH (as a negative control), 10 M of
1,25-(OH)2D3 (as a positive control), and 10 M 1,25-(OH)2D3 analogs (ZK compounds) were digested with two concentrations of
trypsin (10 or 30 g/ml). B, Pull-down assays performed with in vitro translated [35S]VDR and the indicated GST coactivators. VDR
was incubated with EtOH (as a negative control), 100 nM 1,25-(OH)2D3 (as a positive control), and 100 nM 1,25-(OH)2D3 analogs.
C, Gel retardation assays were performed with in vitro translated VDR/RXR heterodimers that were preincubated in the presence
of bacterially expressed GST coactivators with EtOH (as a negative control), 1 M 1,25-(OH)2D3 (as a positive control), 1 M ZK
ligands, and the 32P-labeled DR3-type VDRE. 1,25-(OH)2D3 is shown as 1,25D.
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that the results obtained are applicable to a situation in
which cells express low endogenous receptor levels.
We also performed transient transfections with a
prolactin promoter construct (3000 Prl-CAT), which
contains a VDRE (25), as a model to analyze the role of
1,25-(OH)2D3 and 1,25-(OH)2D3 analogs on a natural
complex promoter (Fig. 3C). Although HeLa cells, a
cervical carcinoma cell line, do not express endoge-
nous prolactin, expression of the pituitary-specific
transcription factor GHF-1 (GH transcription factor-1)/
Pit-1 and VDR causes a marked prolactin promoter
stimulation by 1,25-(OH)2D3 that allows the analysis of
transcriptional regulation in this heterologous cell sys-
tem (25, 26). The dose of VDR ligands required to
obtain the maximal activity was higher in the case of
the prolactin promoter. Thus, the treatment of HeLa
cells with 10 nM 1,25-(OH)2D3 strongly increased the
heterologous promoter (Fig. 3B), whereas this concen-
tration only promoted approximately one third of the
maximal prolactin promoter activation (Fig. 3C). This
discrepancy could be explained because the amount
of transfected VDR used to activate the prolactin pro-
moter in response to 1,25-(OH)2D3 was 3 times higher
than that used to activate the heterologous promoter.
ZK157202 was again more potent than 1,25-(OH)2D3,
and the activity of ZK161422, ZK159222, and
ZK168492 was similar to that found with the 4VDRE
TK-Luc construct in this cell type. Interestingly,
ZK136607, ZK191732, and ZK168289 showed more
agonistic potency in the context of the prolactin
promoter.
The ability of compounds ZK136607, ZK159222,
ZK168492, and ZK191732 to antagonize 1,25-
(OH)2D3-dependent transactivation was tested in HEK
293T cells (Fig. 4, upper panel) and that of compounds
ZK136607, ZK159222, ZK191732, and ZK168289 in
Hela cells (Fig. 4, lower panel). In these assays the
cells, transfected with the 4VDRE TK-Luc plasmid,
were treated with a maximal concentration (1 M) of
the compounds in the absence and presence of 10 nM
of 1,25-(OH)2D3. In HeLa cells, ZK191732 showed the
most significant antagonistic effect, reducing 1,25-
Fig. 3. Influence of 1,25-(OH)2D3 and 1,25-(OH)2D3 Analogs on Transactivation
A, HEK 293T cells were cotransfected with 40 ng of 4VDRE TK-Luc and 12.5 ng of VDR and RXR. B, HeLa cells were
cotransfected with 500 ng of 4VDRE TK-Luc and 80 ng of VDR and RXR. C, HeLa cells were cotransfected with 2.5 g of3000
Prl-CAT and expression vectors for the pituitary transcription factor GHF-1/Pit-1 (0.4 g) and VDR (2.5 g). Cells were treated
for 48 h with graded concentrations of 1,25-(OH)2D3 (1,25D) and ZK compounds. CAT or Luc activity is expressed as fold
induction over the values obtained in EtOH-treated control cells.
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(OH)2D3-dependent promoter activation by 51%,
whereas ZK159222 and ZK168289 alone provided ap-
proximately 50–60% of the maximal induction of re-
porter activity, and only a weak antagonistic effect was
observed after 1,25-(OH)2D3 cotreatment. ZK136607,
which had a null or very weak agonistic effect at lower
doses (see Fig. 3), activated strongly reporter activity
at 1 M and consequently no antagonist effect was
observed in the presence of 1,25-(OH)2D3 in either
HEK 293T or HeLa cells. As occurred with the agonis-
tic effects, antagonist potency was also cell context
dependent. Thus, ZK159222 and ZK191732 showed
more antagonistic activity in HEK 293T cells than in
HeLa cells. ZK191732 was the most antagonistic com-
pound in HEK 293T cells, and the combination of this
compound with 1,25-(OH)2D3 resulted in only 34% of
maximal induction.
Dissociated Activity of VDR Ligands
We have used the retinoic acid receptor (RAR)2
(R140-Luc) and collagenase (73Col-Luc) promoters
as models to study transrepression by VDR ligands
(Figs. 5 and 6). We have previously shown that 1,25-
(OH)2D3 exerts a repressive effect on retinoic acid
(RA)-dependent transactivation of the RAR2 pro-
moter. Competition for DNA binding site and titration
of coactivator proteins are mechanisms suggested to
explain this repression (9, 10). In HEK 293T (Fig. 5A) or
Hela cells (Fig. 5B), as expected, the agonist
ZK161422 and the potential superagonist ZK157202
were able to transrepress even more strongly than
1,25-(OH)2D3. It was expected that the VDR ligands
promoting an incorrect positioning of the AF-2 surface,
which does not allow the interaction of VDR with co-
activators, should not transrepress RA-dependent trans-
activation. Surprisingly, the compounds ZK136607,
ZK159222, ZK168492, ZK191732, and ZK168289, with
null or weak agonistic activity, were also able to promote
transrepression. Furthermore, inhibition was more evi-
dent at low doses, and some of these compounds with
a low transactivation capacity were even more potent
than 1,25-(OH)2D3 to transrepress the RAR2 promoter.
Cell-specific differences in the potency of the VDR li-
gands to inhibit the retinoic acid (RA) response were also
observed. For instance, ZK136607 was more effective
than the natural ligand in HeLa cells, whereas it was less
potent in HEK 293T cells.
We also analyzed the transrepression exerted by the
1,25-(OH)2D3 analogs on 4-12-O-tetradecanoylphor-
bol 13-acetate (TPA)-dependent transactivation of the
collagenase promoter in HEK 293T (Fig. 6A) and HeLa
cells (Fig. 6B). The results obtained with the 73Col-
Luc construct were very similar to those obtained with
the RAR2 promoter in HEK 293T cells: ZK161422 and
ZK157202 were more active than 1,25-(OH)2D3, and all
the compounds with an antagonistic profile were able
to transrepress the effect of TPA. However, in Hela
cells, ZK136607, ZK191732, and ZK168289 transre-
pressed weakly in comparison with 1,25-(OH)2D3 and,
paradoxically, only at low doses. Thus, the dissociated
effect on transrepression vs. transactivation also ap-
pears to depend on the cellular context.
DISCUSSION
In this study, several 1,25-(OH)2D3 derivatives have been
analyzed for their agonistic or antagonistic potential. Re-
sults obtained from the limited protease assays suggest
that ZK136607, ZK168492, ZK191732, and ZK168289
could have low agonistic activity because they stabilize
the VDR conformation c2LPD, which keeps helix 12 in a
displaced position that does not allow an interaction of
VDR with coactivators. The latter mechanism, which is
based on an incorrect positioning and blocking of the
AF-2 domain, has also been suggested for antagonists
of other members of the nuclear hormone receptor su-
perfamily, such as the estrogen receptor (27). In contrast
with these compounds, ZK157202 appears to stabilize
c1LPD even more than 1,25-(OH)2D3. In the presence of
this compound, the shorter fragment c3LPD was only
observed when a high dose of trypsin was used. This
result suggests that this compound could be a potential
superagonist. This agrees with the concept that super-
agonists are able to stabilize the agonistic conformation
for a much longer time than the natural agonist (28).
Although ligand binding increases formation of c1-,
c2-, and c3LPD, these bands are also detected in the
Fig. 4. Antagonism of 1,25-(OH)2D3-Dependent Transacti-
vation
HEK 293T cells (upper panel) and HeLa cells (lower panel)
were transfected with the 4VDRE TK-Luc reporter as in Fig.
3. Cells were treated with 1 M of the ZK analogs indicated in
the absence and presence of 10 nM 1,25-(OH)2D3 (1,25D),
and luciferase activity was determined after 48 h. Data are
expressed relative to the maximal induction obtained in cells
treated with 1,25-(OH)2D3 alone that were considered as
100%.
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absence of ligand, in agreement with the idea that
different VDR conformations exist (29). The production
of c3LPD has been recently linked to a putative VDR
alternative binding pocket that is proposed to be ki-
netically favored by vitamin D sterols (30). Interest-
ingly, it has been proposed that occupation by an
appropriately shaped ligand can lead to the onset of
either rapid or genomic VDR-mediated responses (29).
In all crystal structures of VDR bound to agonist
ligands, a single conformation of the complex is ob-
served: the position and conformation of the activation
helix 12 is strictly maintained (31–33). In this agonistic
conformation, precise positioning of helix 12 via the
H397-F422 interaction creates a distance of 19Å be-
tween the negatively charged E420 on the surface of
helix 12 and the positively charged K246 on the sur-
face of helix 3. This charge clamp structure is essential
for contacting the LXXLL motif of the NR interacting
box of coactivator proteins. In fact, only ZK161422
and ZK157202, but not the other compounds, were
able to induce, as 1,25-(OH)2D3 does, coactivator re-
cruitment in solution and in the presence of RXR and
DNA.
On the other hand, it has been suggested that the
partial antagonist ZK159222 or the full antagonist
ZK168281 adopt an structure in which the last four
carbon atoms extend toward helices 3 and 12 and
steric contacts are observed with A231 (helix 3) and
V418 (helix 12), suggesting that most likely the activa-
tion helix will not be optimally positioned (31, 32).
Molecular dynamics (MD) simulations of VDR’s LBD
have also demonstrated that the extended side chain
of both antagonists prevents the H397-F422 interac-
tion and places helix 12 in a position in which the
distance between residues K246 and E420 deviates
from the optimized value of 19Å. This decreases the
affinity for coactivators or even makes the interaction
impossible. It has been proposed that antagonism by
the 26,23-lactone 1,25-(OH)2D3 analog (TEI-9647) or
by compounds ZK159222 and ZK168281, which con-
tain an extended side chain, results from disturbing
the helix 12 position (31). This is consistent with our
results: ZK168492, ZK191732, and ZK168289 have an
extended side chain as does the ZK159222 1,25-
(OH)2D3 antagonist, and none of these compounds
were able to induce recruitment of p160 coactivators
or DRIP205 either in solution or bound to RXR on DNA.
Thus, these VDR ligands could act as antagonists,
even though some agonistic activity could be ob-
served at high concentrations. Although ZK136607
has a chemical structure very similar to that of the
natural ligand, it has little potency to induce coactiva-
tor recruitment and to transactivate. This compound
binds VDR with a 10-fold lower affinity than the natural
hormone, and a higher concentration appears to be
necessary to achieve an agonistic behavior. In fact,
Fig. 5. Influence of 1,25-(OH)2D3 and 1,25-(OH)2D3 Analogs on RA-Dependent Transactivation of the RAR2 Promoter
A, HEK 293T cells were cotransfected with 200 ng of the RAR2 promoter (R140-Luc), and expression vectors for VDR (12.5
ng), RXR (12.5 ng), and RAR (2.5 ng). B, HeLa cells were cotransfected with 500 ng of the RAR2 promoter and VDR (80 ng), RXR
(80 ng), and RAR (16 ng). After transfection the cells were treated for 48 h with 1 M RA alone or in combination with increasing
concentrations of 1,25-(OH)2D3 (1,25D) or ZK compounds, as indicated. Results are shown as a percentage of the luciferase
activity obtained in the cells treated with RA alone.
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this compound used at 100 nM was unable to promote
binding of coactivators to VDR, but at 1 M induced
partial coactivators recruitment by VDR-RXR in the
supershift assays (Fig. 2C).
Prevention of VDR-RXR complex formation on DNA
could be a mechanism of antagonism in 1,25-(OH)2D3
signaling. However, strong binding to the VDRE in the
presence of the different compounds was found (Fig.
2C), and we have results demonstrating that both
1,25-(OH)2D3 and 1,25-(OH)2D3 analogs equally in-
crease binding of the VDR/RXR heterodimer to DNA
(data not shown). Therefore, prevention of complex
formation is not the cause for the low transcriptional
activity of some ligands. In contrast, the defective
interaction with coactivators appears to be the main
reason why ZK168492, ZK191732, and ZK168289
have a low potency in comparison with 1,25-(OH)2D3
to transactivate VDRE reporter genes. In contrast,
ZK157202, which induced coactivator recruitment,
was even more potent than 1,25-(OH)2D3 in activating
either a heterologous reporter or a natural promoter
and could be described as a superagonist. This com-
pound is not metabolized by the C-24 oxidation path-
way, which allows it to be retained longer inside target
cells, showing a higher biological activity as compared
with 1,25-(OH)2D3 or ZK161422 (23).
Interestingly, some of the VDR ligands used in this
study act in a cell specific-dependent manner because
they lack activity in HeLa cells while presenting some
agonistic activity in HEK 293T cells, or vice versa.
Furthermore, their ability to antagonize the response
to 1,25-(OH)2D3 is also quantitatively different de-
pending on the cell context. This would describe these
compounds as VDRMs. It has been suggested that
ligand-selective cofactor recruitment may underlie
the novel pharmacological properties of ligands that
show preference for osteoblasts over intestinal cells
(18). Very recently, tissue-selective nonsecosteroidal
VDRMs that function as potent agonists in keratino-
cytes, osteoblasts, and peripheral blood mononuclear
cells, but show poor activity in intestinal cells, have
been described (19). Different ligands could induce
different conformational changes in the receptor lead-
ing to selective coactivator recruitment. For instance,
the nonhypercalcemic nonsecosteroidal analogs show
differential recruitment of the coactivator, peroxisomal
proliferator-activated receptor coactivator 1, to E420A
mutant VDR (19). Furthermore, the secosteroidal ana-
log 22-oxa-1,25-dihydroxyvitamin D3 has been de-
scribed to induce interaction of VDR with TIF2 but not
with SRC-1 or amplified in breast cancer 1 (34). This is
not the case with the compounds tested here, which
showed a similar profile for the recruitment of different
p160 coactivators and DRIP205 (Fig. 2), although the
possibility that they could recruit other coactivators
selectively cannot be dismissed.
A most important finding in this work was that the
ZK136607, ZK159222, ZK168492, and ZK191732
Fig. 6. Influence of 1,25-(OH)2D3 and 1,25-(OH)2D3 Analogs on TPA-Dependent Transactivation of the Collagenase Promoter
A, HEK 293T cells were cotransfected with 200 ng of the 73Col-Luc reporter plasmid and 12.5 ng of VDR and RXR. B, HeLa
cells transfected with 500 ng of the reporter plasmid and 80 ng of VDR and RXR. After transfection the cells were treated for 48 h
with 100 nM TPA alone or in combination with the indicated concentrations of 1,25-(OH)2D3 (1,25D) or ZK analogs. Data are shown
as a percentage of the luciferase activity obtained in cells incubated with TPA alone.
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ligands have a dissociated effect, i.e. they have low
capacity to transactivate, but they have potency to
transrepress. Interestingly, these compounds that
were able to inhibit activation of the RAR2 pro-
moter by RA have very little calcemic activity. The
RAR2 promoter contains two RA response ele-
ments (RAREs), but only the proximal RARE ap-
pears to be sufficient to confer 1,25-(OH)2D3-medi-
ated repression (9). We have previously shown that
VDR/RXR can bind to the RARE with high affinity,
but without a defined polarity (10). Binding of the
heterodimer to this element is transcriptionally un-
productive for activating the promoter in response
to 1,25-(OH)2D3, and the competition between ac-
tive RAR/RXR and inactive VDR/RXR for DNA bind-
ing could contribute to transrepression. Accord-
ingly, the VDR ligands tested here could generate a
more stable structure of VDR/RXR on the RARE
and reduce RA-dependent transactivation.
The VDR ligands analyzed also behave as VDRMs in
transrepression because their potency appears to de-
pend on the cell context. Whereas in HeLa and HEK
293T cells all compounds were able to repress the RA
response (Fig. 5), cell-specific differences have been
also observed. Thus, ZK136607 was more active in
HeLa than in HEK 293T cells, being even more potent
than 1,25-(OH)2D3 in blocking the RA response. Thus,
in addition to DNA binding competition, other mech-
anism/s must contribute to the inhibition, among
which cell-specific differences in the metabolism of
the compounds could play a role. The finding, that the
VDR AF-2 domain seems to be required for the dom-
inant negative activity of VDR (9), suggests that titra-
tion of coactivators may also be involved in the inhi-
bition of the RA response by VDR ligands. However, all
the ZK compounds, even those with an antagonistic
profile that do not induce coactivators recruitment,
were able to transrepress the RA response. This find-
ing suggests that other still unidentified cofactors that
bind to both RAR and VDR could be involved in the
transrepression by 1,25-(OH)2D3 in HeLa and HEK 293T
cells. Furthermore, these unidentified cofactors, as op-
posed to the classical coactivators, do not appear to
require an intact AF-2 surface to mediate transrepres-
sion. In agreement with this idea, it has been shown
recently that -catenin interacts with and activates VDR
in a ligand-dependent manner, under conditions in which
other coactivators do not. 1,25-(OH)2D3 induces interac-
tion between -catenin and the AF-2 VDR point mutant
E420Q (35), which has very diminished capacity to bind
classical coactivators (34). Moreover, the partial antago-
nist ZK 159222 was also able to induce -catenin re-
cruitment by VDR (35).
The noncalcemic VDR ligands examined were also
able to repress the response of the AP-1-containing
collagenase promoter to TPA. Again, there is not a
clear correlation between their agonistic activity on
a VDRE and their capacity for AP-1 transrepression,
demonstrating that molecular determinants govern-
ing the transrepressive activity of VDR are likely to
be distinct from those ruling its transactivation po-
tential. Furthermore, also in this case the inhibitory
effect of some of the ZK compounds was more
marked in HEK 293T than in HeLa cells, showing
that they can function as cell-specific VDR modula-
tors. Because the AP-1 complex regulates the ex-
pression of several genes involved in oncogenic
transformation and cellular proliferation, there is
considerable interest in the identification of com-
pounds able to down-regulate AP-1 activity and
thereby oppose unregulated cell growth. A number
of ligands for nuclear receptors display such AP-1-
repressive activity, which seems to be the basis for
their beneficial therapeutic effects. That the VDR
ligands analyzed here are unable to stimulate tran-
scription efficiently but have anti-AP-1 activity is a
novel finding for 1,25-(OH)2D3 analogs, but has been
already described for dissociated glucocorticocoids
(37) and retinoids (38–42), which can inhibit AP-1-
dependent transcription, while only weakly activat-
ing GRE- or RARE-based reporter genes. These
compounds could have an added therapeutic inter-
est because they could be devoid of the deleterious
side effects secondary to activation of genes con-
taining hormone response elements.
In summary, we report here the characterization of
VDR modulators that have not only cell-selective ef-
fects, but also have dissociated activity that distin-
guishes between transactivation and transrepression.
Such compounds may be a valuable tool for studying
molecular mechanisms of VDR signaling and, due to
their low calcemic activity, they could be promising
therapeutic agents.
MATERIALS AND METHODS
VDR Analogs
The chemical names for the 1,25-(OH)2D3 derivatives used
were the following: ZK136607, (5Z,7E)-(3S)-9,10-seco-5,7,
10(19)-cholestatriene-3,25-diol; ZK 157202, (5Z,7E,23E)-
(1S,3R)-20-methyl-9,10-secocholesta-5,7,10(19),23-tetraene-
1,3,25-triol; ZK159222, (5Z,7E,22E)-(1S,3R,24R)-1,3,24-
trihydroxy-26,27-cyclo-9,10-secocholesta 5,7,10(19),22-tet-
raene-25-carboxylic acid butyl ester; ZK161422, (5Z,7E)-
(1S,3R)-20-methyl-9,10-secocholesta-5,7,10(19)-triene-1,3,
25-triol; ZK168289, (5Z,7E,22E)-(1S,3R,24R)-25-(1-oxohexyl)-
26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1,3,24-
triol; ZK168492, (5Z,7E,22E)-(1S,3R,24R)-1,3,24-trihydroxy-
26,27-cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-25-car-
boxylic acid 1,1-dimethyl ester; and ZK191732, (5Z,7E,22E)-(1S,
3R,24R)-25-(1-methylthiazole-2-yl)-26,27-cyclo-9,10-secocho-
lesta- 5,7,10(19),22-tetraene-1,3,24-triol.
VDR Binding Assay
The affinity of the 1,25-(OH)2D3 analogs was determined in
a competition ligand-binding assay as previously de-
scribed (43). Briefly, a VDR preparation was incubated with
[methyl-3H]125-vitamin D3 (1,25-(OH)2D3) in the presence
of increasing concentrations of unlabeled 1,25-(OH)2D3 or
1,25-(OH)2D3 analogs. Bound and unbound material was
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separated by absorption of the free ligand to dextran-
coated charcoal. The radioactivity remaining was counted,
and binding data are expressed as the IC50 [i.e. the con-
centration of cold ligand required to inhibit 50% of labeled
1,25-(OH)2D3 binding].
Calcemic Activity
For measurement of total calcium levels, female mice 8–12
wk old were treated with compounds by sc injection for
5 d, and urine and serum were collected 24 h after com-
pound administration. The vehicle-treated group served as
the control. For measurement of total calcium, samples
were diluted 1:2 with H2O and analyzed for calcium (milli-
moles/liter) by flame photometer AFM 5051 (Eppendorf,
Hamburg, Germany) against a standard curve prepared
from a standard solution containing 5 mM calcium (Eppen-
dorf) as previously described (43). Calcemic activity of the
different VDR ligands was expressed relative to that of
1,25-(OH)2D3. Urine calcium levels in control animals were
significantly elevated (from 2 to 6 mmol/liter) after treat-
ment with 0.03 g/kg/d of 1,25-(OH)2D3. Significant in-
creases of serum calcium after 1,25-(OH)2D3 administra-
tion (from 2.7 to 3.0 mmol/liter) were found with 0.1 g/
kg/d (43). The maximal concentration of 1,25-(OH)2D3 and
ZK analogs used was 10 g/kg/d.
Expression Vectors and Transfections
Expression vectors for wild-type and mutant human RXR,
VDR, and RAR are cloned in pSG5 (9). The constructs
GST-ACTR, GST-TIF-2, GST-SRC-1, and GST-DRIP205
code for the nuclear receptor-interacting domains of these
proteins. These plasmids have already been described (36).
The 3000 PRLCAT plasmid containing the 5-flanking re-
gion of the rat prolactin promoter fused to choramphenicol
acetyl transferase (CAT) was also previously described (25,
26). This reporter (5 g) was transfected in HeLa cells by
calcium phosphate in p60 dishes. The cells were cotrans-
fected with 2.5 g of VDR and 0.4 g of the GHF-1/Pit-1
transcription factor. In 4VDRE TKLuc construct the lucif-
erase reporter gene is driven by four copies of DR3-type
VDRE from the rat ANF gene promoter (20). The R140-Luc
construct contains the fragment 124 to 14 of the human
RAR2 promoter, and the construct 73Col-Luc contains
the collagenase promoter fused to luciferase. These plasmids
were also cotransfected with VDR and RXR as is described
for 4VDRE TK-Luc. HEK 293T cells, grown in 24-well plates,
were transfected with 40 ng of 4VDRE TK-Luc, 200 ng of
R140-Luc, or 200 ng of 73Col-Luc, and the expression
vectors for VDR (12.5 ng), RXR (12.5 ng), or RAR (2.5 ng)
as indicated in the figure legends. HeLa cells, also grown in
24-well plates, were transfected with 500 ng of 4VDRE
TK-Luc, R140-Luc or73Col-Luc and VDR (80 ng), RXR (80
ng), and RAR (16 ng), as indicated in the figures. In all cases,
after transfection cells were plated in medium containing
hormone-stripped serum and, after an overnight incubation,
treatments were started, and luciferase or CAT activity was
determined after 48 h. Experiments were performed with
triplicate cultures, and each experiment was repeated at least
three times. Data are represented as means  SDs.
Limited Proteolytic Digestion
Limited proteolytic assays were performed as described
(36). In vitro-translated [35S]VDR was incubated in the
presence of ethanol or 10 M 1,25-(OH)2D3 or 1,25-(OH)2D3
analogs for 20 min at room temperature. The receptors
were then incubated for 2 min with 10 or 30 g/ml of
trypsin. Proteolysis was stopped by adding SDS sample
buffer, and the proteolytic fragments were separated by
SDS-PAGE in a 12% polyacrylamide gel and identified by
autoradiography.
Gel Retardation Assays
Mobility shift assays were performed with 2.5 l of in
vitro-translated VDR and RXR in the presence and absence
of 400–600 ng of recombinant GST-fused SRC1, ACTR,
TIF 2, or DRIP205 and the consensus DR3 oligonucleotide
5-AGCTCAGGTCAAGGAGGTCAG-3 as previously de-
scribed (25). 1,25-(OH)2D3 and 1,25-(OH)2D3 analogs were
used at 1 M.
GST Pull-Down Assays
Protein-protein interactions were performed with 5 l of in
vitro translated [35S]VDR and the fusion proteins of GST-
ACTR, GST-TIF-2, GST-SRC-1, or GST-DRIP205, or GST
as a control (25, 26). Fifteen minutes before and during the
binding reaction, [35S]VDR is incubated in the presence of
100 nM 1,25-(OH)2D3 or 1,25-(OH)2D3 analogs. The bound
proteins were analyzed by SDS-PAGE in a 10% polyacryl-
amide gel and identified by autoradiography.
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